JPRN-UMIN000031203招募中未知
Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomy - Safety and efficacy of nab-P + Geme in the patients with recurrent pancreatic cancer
niversity of Yamanashi0 个研究点目标入组 30 人开始时间: 2018年2月9日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with allergy for nab-paclitaxel and gemcitabine 2) Patients with severe infection 3) Patients who are considered to be inappropriate for this study
研究者
相似试验
已完成
2 期
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24
已完成
不适用
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancerunresectable pancreas cancerJPRN-UMIN000013206Yokohama City University Hospital Oncology
进行中（未招募）
1 期
Study of Nab-paclitaxel and Gemcitabine in Elderly Patients with Pancreatic CancerMetastatic pancreatic cancerMedDRA version: 17.1 Level: PT Classification code 10033610 Term: Pancreatic carcinoma metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003596-27-ESAsociación de Oncología Médica del Hospital de Cruces (ASONMEC)80
招募中
2 期
Efficacy and safety of nab-paclitaxel plus carboplatin in patients with Carcinoma of unknown primary siteCarinoma of unknown primary site(CUP)JPRN-UMIN000016728Teikyo University School of Medicine30
已完成
2 期
Phase II study of gemcitabine plus nab-Pacletaxel as second-line therapy after FOLFIRINOX for advanced pancreatic canceradvanced pancreatic cancerJPRN-UMIN000016624Gifu University Hospital30